NCT06201507 2024-01-12
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
Phase 2 Unknown
Clinical Trials
40 trialsNCT04877275 2023-12-06
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT03712956 2023-09-21
CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER
European Institute of Oncology
Phase 2 Unknown
NCT00326456 2023-03-27
MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
National Cancer Institute, Naples
Phase 3 Unknown
NCT01802749 2023-03-24
MITO16MANGO2b
National Cancer Institute, Naples
Phase 3 Unknown
NCT05386524 2023-02-16
Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC
Fudan University
Phase 2 Unknown
NCT05656079 2022-12-19
easy laugh
Shanghai Pudong Hospital
Phase NA Unknown
NCT03794778 2022-07-18
Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University
Phase 4 Unknown
NCT05346107 2022-04-26
PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer
Xijing Hospital
Phase 2 Unknown
NCT03071926 2022-04-20
Metronomic PLD in Patients With Primary Endocrine Resistant ABC
Fudan University
Phase 2 Unknown
NCT05302336 2022-04-14
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4 Unknown
NCT05097248 2021-10-28
Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04679064 2021-08-27
NItCHE-MITO33
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Unknown
NCT04765228 2021-02-21
Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma
Fudan University
Phase 2 Unknown
NCT02822157 2021-01-29
CLIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Unknown
NCT03933319 2020-07-08
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT02733380 2020-04-01
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT03994107 2020-01-22
Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
Peking Union Medical College
Phase 1/2 Unknown
NCT04213612 2019-12-30
DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors
Sun Yat-sen University
Phase 1 Unknown
NCT04101812 2019-09-26
Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT03952572 2019-05-16
Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma
Peking University
Phase 3 Unknown
NCT03539328 2018-05-29
MITO27
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT02953184 2017-12-29
Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy
Jilin University
Phase 2 Unknown
NCT03359694 2017-12-02
Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT03335241 2017-11-13
Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT03023358 2017-01-18
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients
Nanfang Hospital, Southern Medical University
Phase 3 Unknown
NCT01541332 2016-03-10
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Oncotherapeutics
Phase 1/2 Unknown
NCT02428751 2015-11-18
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
Sun Yat-sen University
Phase 3 Unknown
NCT01715168 2015-01-15
A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
Azaya Therapeutics, Inc.
Phase 1 Unknown
NCT01388621 2013-08-20
PROVE
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 2 Unknown
NCT01328236 2011-09-22
Bortezomib
Clinical Service, China
Phase 2 Unknown
NCT00518583 2010-01-15
Phase II Study in Patients With Operable Breast Cancer
Aptium Oncology Research Network
Phase 2 Unknown
NCT00946374 2009-07-27
HD-MCL2003
Heidelberg University
Phase 2 Unknown
NCT00886028 2009-04-22
Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
National Institute of CancerologÃa
Phase 2 Unknown
NCT00531973 2009-02-18
LITE
Catholic University, Italy
Phase 4 Unknown
NCT00159094 2008-06-02
A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer
Hematology Oncology Consultants
Phase 2 Unknown
NCT00333008 2006-09-26
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
The Alvin and Lois Lapidus Cancer Institute
Phase 2 Unknown
NCT00250874 2005-11-08
Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer
Zeneus Pharma
Phase 2 Unknown
NCT00006433 2005-06-24
Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer
National Center for Research Resources (NCRR)
Phase 2 Unknown